The Lancet9h
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...
Weight loss jabs DOUBLE risk of deadly condition, major study finds - patients in hospital due to the medication soar
The risks of 'miracle' weight loss jabs such as Ozempic, Wegovy and Mounjaro have been laid bare by a landmark study ...
Popular Weight Loss Drugs Could Affect Your Behavior: Scientists Conduct Genetic Investigation
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Hosted on MSN16h
Weight loss jabs could raise risk of deadly cancer within just one year of use
Popular weight loss injections including Ozempic, Wegovy and Mounjaro could increase the risk of thyroid cancer within the ...
Healio17h
Novel obesity drug induces up to 22% weight loss with no safety concerns
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
TAG24 NEWS on MSN21h
Major study of weight-loss jabs shows slew of benefits but also risks
The risk of heart attack and stroke declines, but gastrointestinal problems and joint inflammation increase: New research has shed more light on the pros and cons of weight-loss jabs.